Skip to main content
. Author manuscript; available in PMC: 2014 Feb 19.
Published in final edited form as: Circ Res. 2012 Mar;110(7):927–937. doi: 10.1161/CIRCRESAHA.112.265140

Figure 3.

Figure 3

99mTc-cAbVCAM1-5 HPLC profiles indicating that this nanobody was stable in vitro at 0 (A) and 6 hours (B) following radiolabeling, as well as in vivo in the blood 3 hours post-injection (C). Representative in vivo SPECT/CT whole body maximum intensity projections images (MIP) of control 99mTc-cAbBcII10 (D) and 99mTc-cAbVCAM1-5 (E) nanobodies obtained 2–3h following i.v. injection in C57Bl/6J mice. 99mTc-cAbVCAM1-5 was taken up at the level of the bladder (Bl) and kidneys (Kd) as well as in the lymphoid tissues : lymph nodes (LN), bone marrow (BM), thymus (Tm) and spleen (Sp).